1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 STAKEHOLDERS 20
1.6 LIMITATIONS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH APPROACH 22
2.1.1 SECONDARY RESEARCH 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY RESEARCH 24
2.1.2.1 Key data from primary sources 24
2.1.2.2 Break down of primaries 25
2.1.2.3 Key industry insights 26
2.2 MARKET SIZE ESTIMATION 27
2.3 DATA TRIANGULATION APPROACH 29
2.4 MARKET SHARE ESTIMATION 30
2.5 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 36
4.1 CUSTOM ANTIBODIES: MARKET OVERVIEW 36
4.2 CUSTOM ANTIBODIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 37
4.3 REGIONAL MIX: CUSTOM ANTIBODIES MARKET (2018–2023) 38
4.4 CUSTOM ANTIBODIES MARKET: DEVELOPED VS. DEVELOPING MARKETS,
2018 VS. 2023 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 MARKET DRIVERS 41
5.2.1.1 Increasing research activity and funding 41
5.2.1.2 Quality concerns over catalog antibodies 42
5.2.1.3 Increasing antibody therapeutics and expanding drug pipeline 43
5.2.1.4 Growing industry-academia collaborations 43
5.2.2 MARKET OPPORTUNITIES 44
5.2.2.1 High growth opportunities in emerging countries 44
5.2.2.2 Increasing demand for personalized medicine and protein therapeutics 45
5.2.2.3 Growth in stem cell and CVD research 46
5.2.2.4 Increasing focus on biomarker discovery 47
5.2.3 MARKET CHALLENGES 47
5.2.3.1 Cost- and time-intensive antibody development processes 47
5.2.3.2 Presence of antibody alternatives 48
5.2.4 INDUSTRY TRENDS 49
5.2.4.1 Increasing focus on antibody-drug conjugates (ADCs) 49
5.2.4.2 Development of bispecific antibodies 50

6 CUSTOM ANTIBODY MARKET, BY SERVICE 51
6.1 INTRODUCTION 52
6.2 ANTIBODY DEVELOPMENT 53
6.2.1 ANTIBODY CHARACTERIZATION 54
6.2.1.1 Characterization eliminates antibodies with heterogeneities that may hamper research studies; this is driving market growth 54
6.2.2 ANTIGEN PREPARATION 56
6.2.2.1 Antigen preparation forms one of the most important steps in the antibody production process 56
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION 57
6.2.3.1 Specific immunization protocols are followed depending on the antibody required and animal used to generate them 57
6.3 ANTIBODY PRODUCTION & PURIFICATION 58
6.4 ANTIBODY FRAGMENTATION & LABELING 60

7 CUSTOM ANTIBODY MARKET, BY TYPE 61
7.1 INTRODUCTION 62
7.2 MONOCLONAL ANTIBODIES 63
7.2.1 MONOCLONAL ANTIBODIES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 63
7.3 POLYCLONAL ANTIBODIES 64
7.3.1 POLYCLONAL ABS ARE PREFERRED IN PROTEOMIC RESEARCH FOR DETECTION OF DENATURED PROTEINS 64
7.4 RECOMBINANT ANTIBODIES 66
7.4.1 RESEARCH REPRODUCIBILITY OFFERED BY THESE ANTIBODIES IS DRIVING THE GROWTH OF THE RECOMBINANT ANTIBODIES SEGMENT 66
7.5 OTHER CUSTOM ANTIBODIES 67
?

8 CUSTOM ANTIBODY MARKET, BY SOURCE 69
8.1 INTRODUCTION 70
8.2 MICE 70
8.2.1 MICE ARE THE MOST PREFERRED HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION 70
8.3 RABBITS 71
8.3.1 ANTIBODIES DEVELOPED IN RABBITS ELIMINATE THE LIMITATION OF SELF-ANTIGEN RECOGNITION IN HUMANS 71
8.4 OTHER SOURCES 73

9 CUSTOM ANTIBODY MARKET, BY RESEARCH AREA 74
9.1 INTRODUCTION 75
9.2 ONCOLOGY 76
9.2.1 USE OF ANTIBODIES HAS GROWN CONSIDERABLY IN CANCER RESEARCH 76
9.3 INFECTIOUS DISEASES 77
9.3.1 ANTIBODIES ARE WIDELY USED IN R&D FOR THE DEVELOPMENT OF VACCINES & THERAPEUTICS AGAINST VARIOUS INFECTIOUS DISEASES 77
9.4 IMMUNOLOGY 79
9.4.1 ASSESSMENT OF CELL SURFACE ANTIGENS USING ANTIBODIES FORMS AN IMPORTANT FIELD OF RESEARCH IN IMMUNOLOGY 79
9.5 NEUROBIOLOGY 80
9.5.1 NEUROBIOLOGY FORMS ONE OF THE FASTEST-GROWING SEGMENTS IN TERMS OF RESEARCH BEING UNDERTAKEN UTILIZING ANTIBODIES 80
9.6 STEM CELLS 81
9.6.1 AVAILABILITY OF HIGH-QUALITY ANTIBODIES HAS BOOSTED STEM CELL RESEARCH 81
9.7 CARDIOVASCULAR DISEASES 83
9.7.1 IDENTIFICATION & CHARACTERIZATION OF CVD BIOMARKERS IS AN IMPORTANT RESEARCH AREA UTILIZING ANTIBODIES 83
9.8 OTHER RESEARCH AREAS 84

10 CUSTOM ANTIBODY MARKET, BY END USER 85
10.1 INTRODUCTION 86
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 87
10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF CUSTOM ANTIBODIES 87
10.3 ACADEMIC & RESEARCH INSTITUTES 88
10.3.1 INCREASE IN DNA SEQUENCING STUDIES AND PROTEOMIC RESEARCH TO DRIVE MARKET GROWTH 88
10.4 CONTRACT RESEARCH ORGANIZATIONS 90
10.4.1 CROS PROVIDE AFFORDABLE OUTLETS FOR COMPANIES AND ACADEMIA TO PURSUE NEW MEDICINES AND OFFER A COST-EFFECTIVE SOLUTION TO DEVELOP DRUGS 90
?

11 CUSTOM ANTIBODY MARKET, BY REGION 92
11.1 INTRODUCTION 93
11.2 NORTH AMERICA 94
11.2.1 US 99
11.2.1.1 Growing research in the field of structure-based drug design and therapeutic mAbs to drive market growth 99
11.2.2 CANADA 102
11.2.2.1 Increasing genomic research to drive the adoption of custom antibodies in the coming years 102
11.3 EUROPE 105
11.3.1 GERMANY 110
11.3.1.1 High investments for the development of ADCs support the growth of the custom antibodies market in Germany 110
11.3.2 UK 113
11.3.2.1 Growing research investments to drive growth in the life science research market, resulting in the growing use of antibodies 113
11.3.3 FRANCE 116
11.3.3.1 Expanding pipeline of therapeutic mAbs along with increasing investments in research are supporting market growth 116
11.3.4 ITALY 119
11.3.4.1 Growing proteomics and genomics research at the academic level to play a key role in market growth in Italy 119
11.3.5 SPAIN 122
11.3.5.1 Increasing focus on the advancement of translational personalized medicine is expected to drive market growth 122
11.3.6 REST OF EUROPE 125
11.4 ASIA PACIFIC 128
11.4.1 JAPAN 133
11.4.1.1 Large number of research initiatives towards the development of various ADCs support market growth in Japan 133
11.4.2 CHINA 136
11.4.2.1 China is one of the fastest-growing markets in the research sector and is expected to dominate the market in the coming years 136
11.4.3 INDIA 139
11.4.3.1 Research for generic mAbs and fusion mAbs as therapeutics is expected to propel the custom antibodies market in the country 139
11.4.4 REST OF ASIA PACIFIC 142
11.5 LATIN AMERICA 146
11.5.1 INCREASING APPLICATIONS OF RESEARCH-SPECIFIC CUSTOM ANTIBODIES TO DRIVE THE GROWTH OF THE MARKET IN THE REGION 146
11.6 MIDDLE EAST & AFRICA 149
11.6.1 GROWING FOCUS OF PHARMACEUTICAL COMPANIES ON THE AFRICAN MARKET IS DRIVING THE MARKET FOR CUSTOM ANTIBODIES IN THE REGION 149
?

12 COMPETITIVE LANDSCAPE 153
12.1 OVERVIEW 153
12.2 MARKET SHARE ANALYSIS 154
12.3 COMPETITIVE SITUATION AND TRENDS 155
12.3.1 PRODUCT & SERVICES LAUNCHES 155
12.3.2 EXPANSIONS 156
12.3.3 ACQUISITIONS 157
12.3.4 OTHER STRATEGIES 157
13 COMPANY PROFILES 159
(Business Overview, Services Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 THERMO FISHER SCIENTIFIC INC. 159
13.2 GENSCRIPT 163
13.3 ABCAM PLC 167
13.4 MERCK GROUP 171
13.5 BIO-RAD LABORATORIES, INC. 175
13.6 CELL SIGNALING TECHNOLOGY, INC. 178
13.7 AGILENT TECHNOLOGIES, INC. 180
13.8 BIOLEGEND, INC. 182
13.9 ROCKLAND IMMUNOCHEMICALS INC. 184
13.10 PROMAB BIOTECHNOLOGIES, INC. 186
13.11 PROTEOGENIX 187
13.12 INNOVAGEN AB 189
*Business Overview, Services Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
14 APPENDIX 190
14.1 INSIGHTS OF INDUSTRY EXPERTS 190
14.2 DISCUSSION GUIDE 191
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 195
14.4 AVAILABLE CUSTOMIZATIONS 197
14.5 RELATED REPORTS 197
14.6 AUTHOR DETAILS 198